WO2009001214A3 - Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists - Google Patents
Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists Download PDFInfo
- Publication number
- WO2009001214A3 WO2009001214A3 PCT/IB2008/001745 IB2008001745W WO2009001214A3 WO 2009001214 A3 WO2009001214 A3 WO 2009001214A3 IB 2008001745 W IB2008001745 W IB 2008001745W WO 2009001214 A3 WO2009001214 A3 WO 2009001214A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrimidin
- isothiazolo
- isoxazolo
- derivatives
- thieno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present invention is directed to novel thieno[2,3-d]pyrimidin-4(3H)-one, isoxazolo[5,4-d]pyrimidin-4(5H)-one and isothiazolo[5,4-d]pyrimidin-4(5H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula (I), wherein the variables R1, R2, R3, X and Z are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94686507P | 2007-06-28 | 2007-06-28 | |
US60/946,865 | 2007-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009001214A2 WO2009001214A2 (en) | 2008-12-31 |
WO2009001214A3 true WO2009001214A3 (en) | 2009-07-23 |
Family
ID=39878037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/001745 WO2009001214A2 (en) | 2007-06-28 | 2008-06-16 | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009001214A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447071B2 (en) | 2014-02-07 | 2016-09-20 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2699157A1 (en) * | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CN105853415A (en) | 2009-05-12 | 2016-08-17 | 罗马克实验室有限公司 | Haloalkyl heteroaryl benzamide compounds |
KR20170141830A (en) | 2009-06-26 | 2017-12-26 | 로마크 레버러토리즈, 엘.씨. | Compounds and methods for treating influenza |
KR101735868B1 (en) | 2010-02-17 | 2017-05-15 | 다케다 야쿠힌 고교 가부시키가이샤 | Heterocyclic compound |
EP2413139B1 (en) | 2010-07-30 | 2015-05-20 | Universität Leipzig | Method and compositions for the identification of agents that have a potential effect against chronic inflammatory diseases |
TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
ES2963218T3 (en) | 2011-12-28 | 2024-03-25 | Global Blood Therapeutics Inc | Intermediates to obtain substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
CN111454200A (en) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | Compounds and their use for modulating hemoglobin |
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
MA41841A (en) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES |
SG10201912511WA (en) | 2015-12-04 | 2020-02-27 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI663160B (en) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde |
TWI778983B (en) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN107235994B (en) * | 2017-08-16 | 2019-05-03 | 石家庄学院 | Simultaneously [3,2-a] pyrimidine -3- acetamide derivative and the application of 5,7- diphenyl -5H- thiazole |
CN107501299B (en) * | 2017-09-06 | 2019-07-16 | 石家庄学院 | Simultaneously [3,2-a] pyrimidine -2- carboxamides derivatives and the application of 5,7- diphenyl -5H- thiazole |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
CN113930791B (en) * | 2021-10-15 | 2023-11-03 | 阜阳师范大学 | Electric synthesis method of pyrido-bipyrimidine tetraketone compound |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0364598A1 (en) * | 1988-03-02 | 1990-04-25 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof |
WO2004041755A2 (en) * | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
WO2004078758A1 (en) * | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
WO2005032527A2 (en) * | 2003-06-10 | 2005-04-14 | Solvay Pharmaceuticals B.V. | Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy |
WO2005061518A1 (en) * | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2006078574A2 (en) * | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2007076085A2 (en) * | 2005-12-22 | 2007-07-05 | Prolexys Pharmaceuticals, Inc . | Fused pyrimidones and thiopyrimidones, and uses thereof |
WO2008012413A2 (en) * | 2006-07-27 | 2008-01-31 | Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) | Pyrimidinone derivatives and their use as a drug |
WO2008064018A1 (en) * | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
-
2008
- 2008-06-16 WO PCT/IB2008/001745 patent/WO2009001214A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0364598A1 (en) * | 1988-03-02 | 1990-04-25 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof |
WO2004041755A2 (en) * | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
WO2004078758A1 (en) * | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
WO2005032527A2 (en) * | 2003-06-10 | 2005-04-14 | Solvay Pharmaceuticals B.V. | Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy |
WO2005061518A1 (en) * | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2006078574A2 (en) * | 2005-01-19 | 2006-07-27 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2007076085A2 (en) * | 2005-12-22 | 2007-07-05 | Prolexys Pharmaceuticals, Inc . | Fused pyrimidones and thiopyrimidones, and uses thereof |
WO2008012413A2 (en) * | 2006-07-27 | 2008-01-31 | Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) | Pyrimidinone derivatives and their use as a drug |
WO2008064018A1 (en) * | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
Non-Patent Citations (5)
Title |
---|
DATABASE REGISTRY Chemical Abstracts Database; 2002, XP002502922 * |
GADAD A K ET AL: "SYNTHESIS AND ANTIHYPERLIPAEMIC ACTIVITY OF SOME 2-AMINOMETHYL-3-ARYL-5,6,7,8-TETRAHYDROBENZO(b)/5,6-DIMETHYLTHIENO(2, 3-d)-PYRIMIDIN-4-ONES", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 46, no. 10, 1 January 1996 (1996-01-01), pages 981 - 988, XP002960408, ISSN: 0004-4172 * |
GRONOWITZ S ET AL: "On thiophene analogues of metaqualonelike compounds", ACTA PHARMACEUTICA SUECICA, XX, vol. 5, 1 January 1968 (1968-01-01), pages 563 - 578, XP008098399, ISSN: 0001-6675 * |
KULSHRESHTHA M J ET AL: "SYNTHESIS OF 2-METHYL, 3-ARYL OR ARYLALKYL 5,6-DIMETHYL OR POLYMETHYLENE THIENO Ä2,3-DÜ-PYRIMIDINE-4-ONES", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 58, no. 10, 1 October 1981 (1981-10-01), pages 982 - 984, XP008047632, ISSN: 0019-4522 * |
RIED, W.; KAHR, E.;: "Zur Kenntnis einiger Thienopyrimidone", LIEBIGS ANNALEN DER CHEMIE, vol. 716, 1968, pages 219 - 221, XP002502704 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447071B2 (en) | 2014-02-07 | 2016-09-20 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Also Published As
Publication number | Publication date |
---|---|
WO2009001214A2 (en) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009001214A3 (en) | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists | |
WO2008041118A3 (en) | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists | |
NZ336560A (en) | 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists | |
CL2008001899A1 (en) | Compounds derived from pyrido [4,3-b] -indole fused, cathepsin k inhibitors; pharmaceutical composition; preparation procedure; and use of the compound in the treatment of diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis and bone metastatic diseases, among others. | |
MX2009003875A (en) | Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain. | |
MY139399A (en) | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist | |
WO2007124181A3 (en) | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use | |
WO2010131922A3 (en) | Amide compound, preparation method thereof and pharmaceutical composition comprising same | |
TW200720279A (en) | Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2(3H)-one derivatives | |
NO20081128L (en) | 4-phenyl-6-substituted-pyrimidine-2-carbonitrile | |
TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
WO2005026126A1 (en) | Crf antagonists and heterobicyclic compounds | |
WO2001066534A3 (en) | Cyclic and bicyclic diamino histamine-3 receptor antagonists | |
UA90707C2 (en) | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
EP1912639A2 (en) | Thiazolopyrimidine kinase inhibitors | |
MX9702731A (en) | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists. | |
HK1091200A1 (en) | Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists | |
EA200801529A1 (en) | CRYSTAL FORMS OF 1-BENZOIL-4- [2- [4-METHOXI-7- (3-METHYL-1H-1,2,4-1-IL) -1 - [(PHOSPHONOXY) METHYL] -1H-PIRROLO [2 , 3-C] PYRIDIN-3-IL] -1,2-DIOXOETHYL] PIPERAZINE | |
TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
IL194057A0 (en) | Pyrimidine, quinazoline, pteridine and triazine derivatives | |
MX2023000580A (en) | 7-(piperidin-1-yl)-4h-pyrimido[1,2-b]pyridazin-4-one derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4. | |
WO2002022616A3 (en) | Alpha v integrin receptor antagonists | |
AU2001277752A1 (en) | Calcium receptor antagonists | |
WO2005118528A3 (en) | Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions | |
AU2002245005A1 (en) | Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08776321 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08776321 Country of ref document: EP Kind code of ref document: A2 |